Nature, Published online: 17 December 2024; doi:10.1038/d41586-024-04102-w Gene-editing technologies for cancer and blood disorders are maturing a little more than a year after the first CRISPR drug was approved.
Increasingly, agricultural scientists in Asia and Africa are using the gene-editing tool CRISPR to develop disease-resistant, high-yield crop varieties. Many, especially those in government research laboratories, are underestimating the importance of the patent and licensing rules that surround tools such as CRISPR. Access the most recent journalism from Nature’s award-winning team Explore the latest features […]
